Explore Moderna's growth potential with FDA-approved respiratory vaccines, strong cash reserves, and a robust pipeline.

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

It’s easy to get caught up in a rally, especially when the S&P 500 keeps pushing and tech stocks feel revitalized. However, in a bull run, there are always weak links. 💵💰Don't miss the move: ...

Sioux City put a damper on Cleburne’s series-winning streak as the Railroaders dropped all three games to the Explorers over ...

The average short interest for the S&P 500 Health Care Index Sector (NYSEARCA:XLV) experienced an increase in June, moving ...

Valued at $13 billion by market cap, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) operates as a clinical-stage ...

The company expects to make the updated Spikevax available to U.S. patients in time for the 2025-26 respiratory virus season.

The FDA this week fully approved Moderna’s COVID-19 vaccine for children aged 6 months to 11 years but limited the approval ...

The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one ...

The U.S. Food and Drug Administration approved "Spikevax," Moderna's vaccine for children aged 6 months to 11 years old. The ...

Moderna’s Covid vaccine for children has been given full FDA approval, making it the first such shot for kids in the U.S.

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the disease, ...